welcome to oneGRAVESvoice
- a positively charged Graves' disease and thyroid eye disease community.- join today!
- log in
Advances in Treatment of Active, Moderate-To-Severe Graves’ Ophthalmopathy
source: The Lancet. Diabetes & Endocrinology
year: 2017
authors: Wiersinga WM
summary/abstract:Graves’ ophthalmopathy is defined as autoimmune inflammation of extraocular muscles and orbital fat or connective tissue, usually in patients with Graves’ disease. About one in 20 patients with Graves’ hyperthyroidism has moderate-to-severe Graves’ ophthalmopathy. Corticosteroids have been the mainstay of treatment, but new evidence about immune mechanisms has provided a basis to explore other drug classes. Intravenous methylprednisolone pulses are more effective and better tolerated than oral prednisone in the treatment of active, moderate-to-severe Graves’ ophthalmopathy. Rituximab has also been suggested as a possible replacement for intravenous corticosteroids.
Two randomised controlled trials of rituximab reached seemingly contradictory conclusions-rituximab was not better with respect to the primary outcome (clinical activity score) than placebo in one trial (which, however, was confounded by rather long Graves’ ophthalmopathy duration), but was slightly better than intravenous methylprednisolone pulses in the other (disease flare-ups occurred only in the latter group). On the basis of evidence published so far, rituximab cannot replace intravenous methylprednisolone pulses, but could have a role in corticosteroid-resistant cases.
Open-label studies of tumour-necrosis-factor-α blockade had limited efficacy, but other studies showed that interleukin-6 receptor antibodies were effective. Results of randomised controlled trials investigating the efficacy of the IGF-1 receptor antibody teprotumumab and the interleukin-6 receptor antibody tocilizumab are expected shortly. Approaches that target the causal mechanism of Graves’ ophthalmopathy (antibodies or antagonists that block thyroid-stimulating-hormone receptors) also look promising.
organization: University of Amsterdam, NetherlandsDOI: 10.1016/S2213-8587(16)30046-8
rareRelated
-
TEPEZZA (teprotumumab-trbw)- Frequently Asked Questions1. What is TEPEZZA? TEPEZZA is the firs...
-
Long-Term Outcomes of Orbital Fat Decompression in Graves’ OrbitopathyPurpose: To evaluate the long-term clin...
-
Mycophenolate Plus Methylprednisolone Versus Methylprednisolone Alone in Active, Moderate-to-Severe Graves’ Or...Background: European guidelines recomme...
-
Selenium in Graves Hyperthyroidism and OrbitopathyPurpose: To review the in vitro and in ...
-
Successful Re-Administration of Low-Dose of Methimazole (MMI) in Graves’ Disease Patients who Experienced Alle...Objective: When patients with Graves' d...
-
Orbital Pain – Dr. Raymond Douglashttps://www.youtube.com/watch?v=qHqEGxMr...
-
How to Prepare for an Appointment With a TED Specialisthttps://www.youtube.com/watch?v=sKQo63E2...